Vimarsana
Biggest News Aggregation in the World

Page 4 - Ohio Engine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ohio Engine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ohio Engine Today - Breaking & Trending Today

GM, Ford To Furlough More Workers As UAW Strike Intensifies - Vimarsana News

GM, Ford To Furlough More Workers As UAW Strike Intensifies

(RTTNews) - General Motors and Ford Motor reportedly said they are furloughing 500 more workers at four plants hit by the ongoing strike by United...

Earthstone Energy Reports Expiration Of HSR Act Waiting Period For Permian Acquisition - Vimarsana News

Earthstone Energy Reports Expiration Of HSR Act Waiting Period For Permian Acquisition

Earthstone Energy, Inc. (ESTE) announced Tuesday the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended, with respect to the previously-announced agreement for Permian Resources Corp.

Ford, GM Layoff Another 500 Workers As Strikes Ripple Across Heartland - Vimarsana News

Ford, GM Layoff Another 500 Workers As Strikes Ripple Across Heartland

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

GM, Ford lay off 500 autoworkers in three states as UAW strike continues - Vimarsana News

GM, Ford lay off 500 autoworkers in three states as UAW strike continues

General Motors Company (NYSE:GM) and Ford Motor Company (NYSE:F) each announced worker furloughs in connection with the United Auto Workers (UAW) strike on...

Kineta Reports Positive Safety, Pharmacokinetic Data For KVA12123 From Ongoing Phase 1/2 Trial - Vimarsana News

Kineta Reports Positive Safety, Pharmacokinetic Data For KVA12123 From Ongoing Phase 1/2 Trial

Kineta, Inc. (KA) announced an update on its ongoing Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123 cleared the first three monotherapy dose levels and was well tolerated with no dose limiting toxicities or cytokine related adverse events observed.